Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1931 1
2000 1
2003 2
2004 2
2005 6
2006 2
2007 5
2008 1
2009 3
2010 3
2011 5
2012 8
2013 18
2014 19
2015 31
2016 38
2017 47
2018 37
2019 30
2020 21
2021 21
2022 14
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26072263

268 results

Results by year

Filters applied: . Clear all
Page 1
Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
Toda H, Nakamura K, Nakahama M, Wada T, Watanabe A, Hashimoto K, Terasaka R, Tokioka K, Nishii N, Miyoshi T, Kohno K, Kawai Y, Miyaji K, Koide Y, Tachibana M, Yoshioka R, Ito H; Tolvaptan Registry Investigators. Toda H, et al. J Cardiol. 2016 Feb;67(2):177-83. doi: 10.1016/j.jjcc.2015.04.017. Epub 2015 Jun 10. J Cardiol. 2016. PMID: 26072263 Free article.
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT. Boertien WE, et al. Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15. Am J Kidney Dis. 2015. PMID: 25600953
Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
Matsue Y, Suzuki M, Nagahori W, Yoshida K, Onishi Y, Satoh Y, Ono Y, Nishioka T, Noda M, Sugi K, Torii S, Tejima T, Sakurada H, Yamaguchi S, Okishige K, Fujii H, Takahashi A. Matsue Y, et al. Cardiovasc Drugs Ther. 2014 Feb;28(1):73-7. doi: 10.1007/s10557-013-6491-8. Cardiovasc Drugs Ther. 2014. PMID: 24048511 Clinical Trial.
Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
Katsumata M, Hirawa N, Sumida K, Kagimoto M, Ehara Y, Okuyama Y, Fujita M, Fujiwara A, Kobayashi M, Kobayashi Y, Yamamoto Y, Saka S, Yatsu K, Fujikawa T, Toya Y, Yasuda G, Tamura K, Umemura S. Katsumata M, et al. Clin Exp Nephrol. 2017 Oct;21(5):858-865. doi: 10.1007/s10157-016-1379-0. Epub 2017 Feb 11. Clin Exp Nephrol. 2017. PMID: 28190113 Free PMC article.
Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y; AVCMA investigators. Suzuki S, et al. Int Heart J. 2015;56(2):213-8. doi: 10.1536/ihj.14-248. Epub 2015 Feb 23. Int Heart J. 2015. PMID: 25740399 Free article. Clinical Trial.
Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
Higashi K, Murakami T, Ishikawa Y, Itoi T, Ohuchi H, Kodama Y, Honda T, Masutani S, Yamazawa H, Senzaki H, Ishikawa S. Higashi K, et al. Int J Cardiol. 2016 Feb 15;205:37-42. doi: 10.1016/j.ijcard.2015.12.003. Epub 2015 Dec 15. Int J Cardiol. 2016. PMID: 26710331
268 results